ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data

Steglatro cut heart failure patients' risk of total hospitalizations, total hospitalizations or death, and first hospitalizations regardless of a prior heart failure, according to new subdata presented Monday at the European Society of Cardiology virtual annual meeting.